1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P3523
    KGDS
    Activator 99.78%
    KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser.
    KGDS
  • HY-P6009A
    Cys-αvβ6-BP TFA
    Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide.
    Cys-αvβ6-BP TFA
  • HY-P6351
    c(avb6)-DOTA TFA
    c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic.
    c(avb6)-DOTA TFA
  • HY-101720A
    Fradafiban hydrochloride
    Antagonist 99.96%
    Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
    Fradafiban hydrochloride
  • HY-10309
    Sibrafiban
    Antagonist 99.67%
    Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
    Sibrafiban
  • HY-P10045
    Integrin signaling inhibitor, mP13
    Inhibitor 99.94%
    Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction.
    Integrin signaling inhibitor, mP13
  • HY-P0309
    Arg-Gly-Glu-Ser
    Control
    Arg-Gly-Glu-Ser is a polypeptide related to RGD and is a negative control for Arg-Gly-Asp-Ser (HY-12290).
    Arg-Gly-Glu-Ser
  • HY-147079A
    Egaptivon pegol sodium
    Inhibitor
    Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.
    Egaptivon pegol sodium
  • HY-P990667B
    STX-100 (Biotinylated)
    Inhibitor ≥99.0%
    STX-100 (Biotinylated) is a biotin-labeled STX-100 (HY-P990667). STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6).
    STX-100 (Biotinylated)
  • HY-N0416R
    Cucurbitacin B (Standard)
    Inhibitor
    Cucurbitacin B (Standard) is the analytical standard of Cucurbitacin B. This product is intended for research and analytical applications. Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids and is oral active. Cucurbitacin B inhibits tumor cell growth, migration and invasion and cycle arrest, but induces cell apoptosis. Cucurbitacin B has potent anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, neuroprotective activity.
    Cucurbitacin B (Standard)
  • HY-P99560
    Tadocizumab
    Inhibitor
    Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.
    Tadocizumab
  • HY-P3533
    EILEVPST
    98.99%
    EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis.
    EILEVPST
  • HY-P4907
    RGD Negative Control
    Control 99.91%
    RGD Negative Control is the negative control of RGD (HY-P0278).
    RGD Negative Control
  • HY-147079
    Egaptivon pegol
    Inhibitor
    Egaptivon pegol (ARC1779) is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol has anti-thrombotic efficacy.
    Egaptivon pegol
  • HY-14921
    Elsibucol
    Inhibitor 99.35%
    Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury.
    Elsibucol
  • HY-P1868
    α2β1 Integrin Ligand Peptide
    98.92%
    α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
    α2β1 Integrin Ligand Peptide
  • HY-P4896
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro
    Inhibitor
    FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis.
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro
  • HY-P5038
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)
    98.11%
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells.
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)
  • HY-P990667
    STX-100
    Inhibitor 99.99%
    STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    STX-100
  • HY-P6438
    Alkyne-cRGD
    Modulator 99.34%
    Alkyne-cRGD is an integrin ligand. Alkyne-cRGD can be used in the study of degraders. Alkyne-cRGD undergoes copper-catalyzed azide-alkyne cycloaddition reaction.
    Alkyne-cRGD
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.